Inborn errors of purine-pyrimidine metabolism

Allena Pharmaceuticals Provides Update on Clinical Development Programs

Retrieved on: 
Monday, July 12, 2021
Nitrogen cycle, Triketones, Uric acid, Branches of biology, Inborn errors of purine-pyrimidine metabolism, Kidney, Organ systems, Anatomy, Acute uric acid nephropathy, Hyperuricemia

Evaluation of clinical and laboratory parameters revealed no significant safety signals and no serious adverse events were reported.

Key Points: 
  • Evaluation of clinical and laboratory parameters revealed no significant safety signals and no serious adverse events were reported.
  • Key bioactivity endpoints will include serum uric acid level, 24-hour urine uric acid level, and renal clearance of uric acid.
  • Allena Pharmaceuticals, Inc.is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.
  • All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.

LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients

Retrieved on: 
Thursday, July 1, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Uric acid, Enzymes, Inborn errors of purine-pyrimidine metabolism, Medical specialties, Organic compounds, Hyperuricemia, Xanthine oxidase inhibitor, Gout, Xanthine oxidase, LG Corporation, LC350189, Gout, LG Chem, LC350189, Gout, LG CHEM

LG Chem announced topline results for the phase 2 study evaluating the efficacy and safety profiles of LC350189, a novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

Key Points: 
  • LG Chem announced topline results for the phase 2 study evaluating the efficacy and safety profiles of LC350189, a novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.
  • LG Chem had received FDA clearance to commence a Phase 2 trial of LC350189 in June 2019 and conducted the Phase 2 study (CLUE study, NCT03934099) with 156 gout patients at 45 clinical sites in the US.
  • Many gout patients could benefit from medicines with improved efficacy and safety profiles from the current standard of care.
  • About LG Chem Life Sciences:
    LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.

Global Gout Markets, Epidemiology and Patient Flow Report 2020-2035: Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, Other Health, Medical specialties, Arthritis, Clinical medicine, Rheumatology, Inborn errors of purine-pyrimidine metabolism, Medicine, Gout, Uric acid, Epidemiology

b'The "Global Gout Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Gout Epidemiology and Patient Flow Analysis - 2021, provides Gout epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Gout Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Gout Epidemiology and Patient Flow Analysis - 2021, provides Gout epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Gout patients, history of the disease at the population level (Gout prevalence, Gout incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Gout patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Gout market sizing, assessing market potential, and developing drug forecast models\nIdentify Gout patients segments through age groups, gender, and disease sub-types\n'

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

Retrieved on: 
Monday, May 10, 2021
Uric acid, Chemical compounds, Inborn errors of purine-pyrimidine metabolism, Organic compounds, Medical specialties, SLC22A12, Solute carrier family, Rheumatology, Hyperuricemia, Gout, Lesinurad

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.

Key Points: 
  • Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.
  • Hyperuricemia has also been implicated in the progression of chronic kidney disease and heart failure, and Dotinurad may potentially play a critical role in helping treat these conditions.\nUnder the terms of the agreement, the Company acquired exclusive development and marketing rights in North America and Europe from Fuji.
  • Fuji is eligible to receive upfront, development and commercial milestone and royalty payments from the Company.
  • Three Japanese Phase 3 trials were completed and more than 500 patients with gout or hyperuricemia were dosed with Dotinurad for up to 58 weeks.

First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout

Retrieved on: 
Thursday, March 25, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Health, Medicine, Rheumatology, Uric acid, Inborn errors of purine-pyrimidine metabolism, Gross pathology, Tophus, Gout, Clinical trial, Pegloticase, ULT, KRYSTEXXA, Horizon

"When we successfully treat patients with KRYSTEXXA we can reduce the uric acid levels and resolve tophi.

Key Points: 
  • "When we successfully treat patients with KRYSTEXXA we can reduce the uric acid levels and resolve tophi.
  • The Four-Weekly Administration for Urate Reduction (FORWARD) is an adaptive, staggered-start trial designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of KRYSTEXXA administered monthly (Q4W).
  • In total, the trial aims to enroll up to 30 adults with uncontrolled gout.
  • The FORWARD trial complements our clinical trial assessing shorter-infusion duration options, which enrolled its first patient last fall and continues our efforts to evolve the patient experience with KRYSTEXXA.

CreakyJoints Launches The Gout Show, a New Podcast Series and Educational Campaign

Retrieved on: 
Tuesday, December 15, 2020
Science, Women, Seniors, Research, MEN, General Health, Health, Consumer, Medical specialties, Medicine, Rheumatology, Clinical medicine, Inborn errors of purine-pyrimidine metabolism, Arthritis, Gout, Uric acid, Chronic condition

In addition to the podcast, there are three bonus patient audio guides about gout diagnosis, risk factors, and the treatment landscape.

Key Points: 
  • In addition to the podcast, there are three bonus patient audio guides about gout diagnosis, risk factors, and the treatment landscape.
  • The Gout Show section of the CreakyJoints website ( creakyjoints.org/thegoutshow ) includes a quiz about uncontrolled gout, and robust educational and support articles specific to gout.
  • Too many people suffer from uncontrolled gout, and The Gout Show speaks directly to them with positive messages of hope and help.
  • CreakyJoints also publishes the popular Raising the Voice of Patients series, which are downloadable patient-centered educational and navigational tools for managing chronic illness.

Rising Patient Pool and Increasing Healthcare Expenditure to Invite Favorable Growth Prospects for Gout Therapeutic Market during 2019-2027: TMR

Retrieved on: 
Thursday, November 19, 2020
Life sciences, Medical specialties, Health sciences, Rheumatology, Inborn errors of purine-pyrimidine metabolism, Uric acid, Arthritis, Biotechnology, Gout, Biopharmaceutical

Thus, the swelling numbers of alcohol consumers may serve as a vital growth-generating factor for the gout therapeutic market .

Key Points: 
  • Thus, the swelling numbers of alcohol consumers may serve as a vital growth-generating factor for the gout therapeutic market .
  • The heightening awareness about the benefits of gout therapy may serve as a prominent growth booster for the gout therapeutic market.
  • The rise in innovations in the biologics field is further inviting immense growth prospects for the gout therapeutic market.
  • The cost-effectiveness of drugs related to gout is also a notable factor that positively influences the growth of the gout therapeutic market.

Rising Patient Pool and Increasing Healthcare Expenditure to Invite Favorable Growth Prospects for Gout Therapeutic Market during 2019-2027: TMR

Retrieved on: 
Thursday, November 19, 2020
Life sciences, Medical specialties, Health sciences, Rheumatology, Inborn errors of purine-pyrimidine metabolism, Uric acid, Arthritis, Biotechnology, Gout, Biopharmaceutical

Thus, the swelling numbers of alcohol consumers may serve as a vital growth-generating factor for the gout therapeutic market .

Key Points: 
  • Thus, the swelling numbers of alcohol consumers may serve as a vital growth-generating factor for the gout therapeutic market .
  • The heightening awareness about the benefits of gout therapy may serve as a prominent growth booster for the gout therapeutic market.
  • The rise in innovations in the biologics field is further inviting immense growth prospects for the gout therapeutic market.
  • The cost-effectiveness of drugs related to gout is also a notable factor that positively influences the growth of the gout therapeutic market.

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

Retrieved on: 
Tuesday, September 8, 2020
Uric acid, Medical specialties, Inborn errors of purine-pyrimidine metabolism, Clinical medicine, Medicine, Hyperuricemia, Gout, Uricemia, Chronic kidney disease, Probenecid, Hyperuricosuria

Increased uric acid excretion in the urine and hyperuricemia are also associated with kidney stone formation and kidney damage.

Key Points: 
  • Increased uric acid excretion in the urine and hyperuricemia are also associated with kidney stone formation and kidney damage.
  • CKD patients with hyperuricemia and gout are often not optimally managed due to limitations of available therapies, including decreased tolerability, dose restrictions, drug-drug interactions, and contraindications.
  • Allena expects to report initial clinical data in the fourth quarter of 2020, subject to the impact of COVID-19.
  • Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.

Selecta Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 8, 2020
Clinical medicine, Medical specialties, Health, Rheumatology, Inborn errors of purine-pyrimidine metabolism, Uric acid, Arthritis, Gout, Immunotherapy, Biopharmaceutical

Selecta is committed to utilizing ImmTOR to potentially improve the efficacy of biologics, enable re-dosing of life-saving gene therapy, and create novel immunotherapies for autoimmune diseases.

Key Points: 
  • Selecta is committed to utilizing ImmTOR to potentially improve the efficacy of biologics, enable re-dosing of life-saving gene therapy, and create novel immunotherapies for autoimmune diseases.
  • Selectas late-stage product candidate, SEL-212, is designed to be a monthly treatment for chronic refractory gout, a debilitating rare disease with a significant unmet medical need.
  • SEL-212 consists of a combination of its ImmTOR platform co-administered with pegadricase, an enzyme designed to treat patients with symptomatic gout, refractory to standard uric acid lowering treatment.
  • Selecta is based in Watertown, Massachusetts.